NASDAQ:FBIO Fortress Biotech Q2 2025 Earnings Results & Report $1.82 +0.11 (+6.43%) Closing price 04:00 PM EasternExtended Trading$1.82 0.00 (-0.11%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Fortress Biotech missed analyst earnings expectations but beat on revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.46 versus the -$0.31 consensus estimate, while revenue of $16.41 million topped the $14.53 million estimate by $1.88 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call DateAugust 12, 2025Conference Call4:00 PM ET Fortress Biotech EPS ResultsActual EPS-$0.46Consensus EPS -$0.31Beat/MissMissed by -$0.15One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersFortress Biotech Revenue ResultsActual Revenue$16.41 millionExpected Revenue$14.53 millionBeat/MissBeat by +$1.88 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fortress Biotech Q2 2025 Earnings FAQ Did Fortress Biotech beat earnings estimates for Q2 2025? Fortress Biotech (NASDAQ:FBIO) reported earnings of -$0.46 per share for Q2 2025, missing the consensus estimate of -$0.31. The report was announced on Thursday, August 14, 2025. What was Fortress Biotech's revenue for Q2 2025? Fortress Biotech reported revenue of $16.41 million for Q2 2025, against a consensus estimate of $14.53 million. Fortress Biotech Earnings HeadlinesFortress Biotech: 3 Key Takeaways for Long-Term InvestorsNovember 13, 2026 | fool.comFortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsNovember 13, 2026 | globenewswire.comThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 17 at 1:00 AM | Porter & Company (Ad)Fortress Biotech, Inc. (FBIO) Q3 2026 Earnings Call TranscriptNovember 12, 2026 | seekingalpha.comFortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)November 10, 2026 | globenewswire.comFortress Biotech (FBIO) Projected to Post Earnings on MondayNovember 9, 2026 | americanbankingnews.comSee More Fortress Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fortress Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortress Biotech and other key companies, straight to your email. Email Address About Fortress BiotechFortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development. Products are commercialized primarily in the United States, directly or through affiliated companies. Founded in 2006, Fortress Biotech has also established and supported subsidiary and affiliate companies to develop and commercialize therapeutic programs. The company is led by founder Lindsay A. Rosenwald, M.D., who serves as its chairman, president and chief executive officer.View Fortress Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.